Key Drivers
- Strong Net Cash
- Rapid Cash Burn
- Ongoing Dilution
AIAI Summary
REPL's investment case hinges on verifying TujuCare's true FDA/label status and proving early launch adoption fast enough to offset roughly $76M quarterly cash burn and avoid dilutive financing; absent confirmed revenue traction, the stock appears to price in more success than its balance sheet supports.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Net Cash
- •Rapid Cash Burn
- •Ongoing Dilution
REPL has strong net cash and liquidity, but rapid cash burn, no revenue, heavy R&D losses, rising leverage, and shareholder dilution create significant funding and execution risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Elevated RSI
REPL is in a short-term downtrend; defend $12.87–$12.92 and reclaim $13.30 to improve the setup, while a break below support risks further volatility.
Sharp rally followed by an 11.5% decline over the last month
Sentiment & News
Key News Insights:
- •Securities Litigation
- •FDA Disclosure
- •Share Decline
Replimune faces securities class-action scrutiny over alleged undisclosed FDA concerns surrounding RP1 trial design and efficacy evidence, heightening investor risk after a sharp share-price decline.
The litigation and regulatory allegations could sustain negative pressure on REPL shares pending clearer FDA and trial-data updates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings